FORM 6-K
 
 
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
 
the Securities Exchange Act of 1934
 
For the month of May 2017
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
 
 
1 Francis Crick Avenue
 
Cambridge Biomedical Campus
 
Cambridge CB2 0AA
 
 United Kingdom
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X            Form 40-F  __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes  __                 No X
 
 
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
24 May 2017 15:00 BST
 
 
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
 
 
AstraZeneca PLC (the Company) announces that, on 23 May 2017, it was notified by Mark Mallon, a Person Discharging Managerial Responsibilities of the Company, that, on 23 May 2017, Mr Mallon sold 20,000 American Depositary Shares (ADSs). Two ADSs are equivalent to one ordinary share of $0.25 in the Company.
 
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
 
1
 
Details of the person discharging managerial responsibilities / person closely associated
 
a)
 
Name
 
Mark Mallon
 
2
 
Reason for the notification
 
a)
 
Position/status
 
Person Discharging Managerial Responsibilities
 
b)
 
Initial notification /Amendment
 
Initial notification
 
3
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
AstraZeneca PLC
 
b)
 
LEI
 
PY6ZZQWO2IZFZC3IOL08
 
4
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
a)
 
Description of the financial instrument, type of instrument
Identification code
 
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
 
b)
 
Nature of the transaction
 
Sale of AstraZeneca PLC American Depositary Shares
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
US$ 33.900214
 
20,000
 
d)
 
Aggregated information
- Aggregated volume
- Price
 
Not applicable - single transaction
 
e)
 
Date of the transaction
 
23 May 2017
 
f)
 
Place of the transaction
 
NYSE
 
 
About AstraZeneca
 
 
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 
Media Enquiries
 
 
 
Esra Erkal-Paler
 
UK/Global
 
+44 203 749 5638
 
Karen Birmingham
 
UK/Global
 
+44 203 749 5634
 
Rob Skelding
 
UK/Global
 
+44 203 749 5821
 
Jacob Lund
 
Sweden
 
+46 8 553 260 20
 
Michele Meixell
 
US
 
+1 302 885 2677
 
Investor Relations
 
 
 
Thomas Kudsk Larsen
 
 
+44 203 749 5712
 
Craig Marks
 
Finance, Fixed Income, M&A
 
+44 7881 615 764
 
Henry Wheeler
 
Oncology
 
+44 203 749 5797
 
Mitchell Chan
 
Oncology
 
+1 240 477 3771
 
Lindsey Trickett
 
Cardiovascular & Metabolic Diseases
 
+1 240 543 7970
 
Nick Stone
 
Respiratory
 
+44 203 749 5716
 
Christer Gruvris
 
Autoimmunity, Neuroscience & Infection
 
+44 203 749 5711
 
US toll free
 
 
+1 866 381 7277
 

 
Adrian Kemp
Company Secretary, AstraZeneca PLC
 
 
 
SIGNATURES
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
AstraZeneca PLC
 
Date: 24 May 2017
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary